Adamas Pharmaceuticals Inc
Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | |
|---|---|---|---|---|---|---|
| Revenue | $74.5M | $54.6M | $2.6M | $571,000 | $572,000 | $1.9M |
| Operating income | −$44.2M | −$92.2M | −$115.0M | −$87.9M | −$61.0M | −$57.4M |
| Net income | −$57.4M | −$105.2M | −$35.0M | −$16.0M | −$13.8M | −$51.8M |
| Total assets | $120.0M | $162.2M | $234.8M | $186.2M | $142.5M | $128.7M |
| Total liabilities | $170.0M | $163.1M | $144.9M | $120.0M | $10.3M | $12.6M |
| Equity | −$50.0M | −$893,000 | $89.9M | $66.1M | $132.2M | $116.2M |
| EPS (diluted) | — | — | — | — | $-2.77 | $-2.86 |
| Shares out. | 28.0M | 27.4M | 26.8M | 22.2M | 21.4M | 17.6M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2020- Operating margin
- −59.3%
- Net margin
- −77.1%
- Return on equity
- 114.9%
- Return on assets
- −47.8%
- Return on capital (ROCE)
- −51.9%
- Liabilities / assets
- 141.6%
- Debt / equity
- —
- Book value / share
- $-1.78
- Revenue growth (YoY)
- 36.3%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2020- Altman Z″ (distress)
- -12.30distress
- Accruals / assets
- −5.6%clean
- Beneish M-Score
- -2.51normal
- Piotroski F-Score
- 4/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 2 severe● 4 warning● 3 good- Negative shareholder equity
- Altman Z″ in the distress zone
- Operating losses (negative operating margin)
- Reported a net loss
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- Strong return on equity (>15%)
- Revenue is growing year-over-year
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Material events
SEC Form 8-K · most recent- Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylawsNov 24, 2021
- Entered a material agreement · Other material eventOct 12, 2021
- Results of operationsAug 9, 2021
- Director / officer changeJun 11, 2021
- Shareholder voteJun 4, 2021
- Results of operationsMay 10, 2021
- Other material eventFeb 25, 2021
- Results of operationsFeb 23, 2021
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.